Breaking Finance News

Clinigen Group (LON:CLIN) stock price target held steady at 1,000.00GBX, released a report earlier today by Peel Hunt

Having a price of 762.00GBX, Clinigen Group (LON:CLIN) traded 1.60% higher on the day. With the last close up 24.59% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Clinigen Group has recorded a 50-day average of 694.15GBX and a two hundred day average of 611.62GBX. Volume of trade was up over the average, with 5,933,653 shares of CLIN changing hands over the typical 500,351

Stating a potential upside of 0.31%, Peel Hunt hold steady the price target of Clinigen Group (LON:CLIN) at 1,000.00GBX

On Wednesday September 28, 2016, Stifel released a statement on Clinigen Group (LON:CLIN) maintained the target price at 800.00GBX that suggested an upside of 0.13%.

Performance Chart

Clinigen Group (LON:CLIN)

With a total market value of 0 GBX, Clinigen Group has price-earnings ratio of 64.58 with a one year low of 492.75GBX and a one year high of 793.50GBX .

A total of 5 brokers have issued a report on the stock. 3 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 0 brokers rating the stock a hold, zero analysts rating the company a underperform, and finally 0 equity analysts rating the company a sell with a one year target of 850.00GBX.

General Information About Clinigen Group (LON:CLIN)

Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). The CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. The MA segment specializes in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies. The GA segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these often-essential drugs. The SP segment manufactures and distributes its own and in-license specialist, hospital-only medicines.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.